Levodopa-responsive dystonia, parkinsonism, and treatment-resistant schizoaffective disorder in Williams syndrome
2024

Levodopa and Movement Disorders in Williams Syndrome

Sample size: 2 publication Evidence: low

Author Information

Author(s): Nikolai Gil D. Reyes, Nathaniel Bendahan, Emily Swinkin, Anthony E. Lang, Anne S. Bassett

Primary Institution: University of Toronto

Hypothesis

Can levodopa effectively treat movement disorders and schizoaffective disorder in individuals with Williams syndrome?

Conclusion

Levodopa may be a safe and effective treatment for movement disorders associated with antipsychotic use in individuals with Williams syndrome.

Supporting Evidence

  • Both patients had treatment-resistant schizoaffective disorder requiring multiple antipsychotic trials.
  • Levodopa treatment led to marked improvement in parkinsonism and partial improvement in dystonia.
  • The study suggests potential shared underlying mechanisms for movement disorders in Williams syndrome.

Takeaway

This study looked at two women with a rare condition called Williams syndrome who got better when they took a medicine called levodopa for their movement problems.

Methodology

The study involved detailed case reports of two adults with Williams syndrome, reviewing their medical histories, treatments, and responses to levodopa.

Limitations

The study is based on only two case reports, limiting generalizability.

Participant Demographics

Both participants were middle-aged women with confirmed Williams syndrome.

Digital Object Identifier (DOI)

10.1007/s10072-024-07705-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication